<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934452</url>
  </required_header>
  <id_info>
    <org_study_id>NRA6180080</org_study_id>
    <secondary_id>A6181209</secondary_id>
    <nct_id>NCT01934452</nct_id>
  </id_info>
  <brief_title>Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients</brief_title>
  <acronym>APERCU</acronym>
  <official_title>Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study will investigate the characteristics of mRCC patients at time of CR in
      comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some
      answers/ refection leads to the following questions :

      Can we identify blood specificity at time of CR vs non on CR? Shall we distinguish CR with
      sunitinib alone from combined CR (sunitinib with local treatment), while in clinical report
      these 2 cohorts present similar time to recurrence (ALBIGES, ASCO 2010)? Can we identify
      potential predictive serum biomarkers of recurrence? (With the aim of isolating blood
      biomarker that can help on treatment discontinuation decision?)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to describe the characteristics of mRCC patients on CR
      with Sunitinib (Cases) and compare them to the characteristics of mRCC patients non on CR
      (controls) in order to identify factors associated with the occurrence of complete remission.

      The results obtained on the sample must be representative of the population targeted by the
      study. The most appropriate method to obtain a representative sample is probability sampling.

      A sample size of N = 40 (cases) and N = 80 (Controls) will provide a power of 80% in the
      detection of a frequency difference between cases and controls corresponding to an OR of 0.24
      for a parameter frequency 10% in control arm and an OR of 0.30 for a parameter frequency of
      around 30% in control arm. The significance level was set at bilateral 5%.

      The data will be analyzed using SAS software (version 9.1 - SAS Institute, North Carolina,
      United States).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characteristics of study patients</measure>
    <time_frame>Baseline up to 36 months</time_frame>
    <description>To compare characteristics of mRCC patients with CR versus mRCC patients without CR with Sutent, in order to identify factors associated with remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRCC patients with CR</measure>
    <time_frame>Baseline up to 36 months</time_frame>
    <description>To describe if mRCC patients with CR maintain or discontinue Sutent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence (rate) or Absence of blood biomarkers</measure>
    <time_frame>Baseline up to 36 months</time_frame>
    <description>To identify biomarkers (FGF, IL8, VEGF...) of complete response and relapse/progression if occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence (rate) or Absence of blood biomarkers</measure>
    <time_frame>Baseline up to 36 months</time_frame>
    <description>To compare the biomarkers previously identified between the 2 arms (patients with CR versus patients without CR)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Complete Remission in Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Complete Remission</arm_group_label>
    <description>Complete remission arm in mRCC patients treated with sunitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Complete Remission</arm_group_label>
    <description>Non complete remission arm in mRCC patients treated with sunitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months</description>
    <arm_group_label>Complete Remission</arm_group_label>
    <other_name>Cases</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months</description>
    <arm_group_label>Non Complete Remission</arm_group_label>
    <other_name>Controls</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        complete remission in mRCC patients treated with sunitinib versus non complete remission in
        mRCC patients treated with sunitinib
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic renal cell carcinoma, histopathologically confirmed

          -  Treated with sunitinib according to Smpc

          -  For cases: Achieving a CR (local assessment according to RECIST V1.0 criteria) with
             Sunitinib in prior 6 months alone OR in combination with local treatment (surgery,
             radiation therapy, ablative techniques: cryotherapy, RFA)

          -  For controls: Life expectancy &gt; 3 months No prior Sunitinib treatment

          -  Patient &gt;18 years

        Exclusion Criteria:

          -  Sunitinib administered in a non-approved label

          -  For cases: CR occurring without sunitinib treatment

          -  For controls: Prior systemic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <state>Cedex 5</state>
        <zip>13335</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU HOTEL DIEU - Service Urologie</name>
      <address>
        <city>Angers Cedex</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes / Hôpital de jour</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273 Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Timone Adultes</name>
      <address>
        <city>Marseille Cedex</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Chirurgicale de l'Orangerie, Chiliotherapie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=NRA6180080&amp;StudyName=Prospective%20Observational%20Analysis%20Of%20CR%20With%20Sunitinib%20Treatment%20In%20mRCC%20Patients%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>complete remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

